Artelo Biosciences, Inc.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company specializing in developing and commercializing treatments that modulate the endocannabinoid system. The company's product candidate pipeline includes synthetic G protein-coupled receptor agonist ART27.13 for anorexia associated with cancer, synthetic cannabidiol cocrystal ART12.11 for inflammatory bowel disease and PTSD, and fatty acid binding protein 5 inhibitor ART26.12 for prostate and breast cancer treatment, as well as PTSD. Artelo Biosciences, Inc. generates revenue through the development and potential commercialization of these innovative treatments targeting various medical conditions.

Products

• ART27.13 - Synthetic G protein-coupled receptor agonist

• ART12.11 - Synthetic cannabidiol cocrystal

• ART26.12 - Fatty acid binding protein 5 inhibitor